Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC
Agreement provides Vector access to FDA-registered, cGMP facility and supports development of 24 novel shelf-stable peptide formulations targeting the $80.8 billion peptide market MEQUON, Wis., May 11, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


